Literature DB >> 3926897

Human lymphocyte responses to hepatitis A virus-infected cells: interferon production and lysis of infected cells.

I Kurane, L N Binn, W H Bancroft, F A Ennis.   

Abstract

Peripheral blood mononuclear cells (PBMC) from nonimmune healthy donors who did not have antibody to hepatitis A virus lysed hepatitis A virus-infected BS-C-1 cells to a greater degree than uninfected BS-C-1 cells. The predominant effector cells were contained in the nonadherent peripheral blood lymphocyte (PBL) fraction, although some lytic activity was associated with adherent cells. Characterization of the PBL with monoclonal antibodies showed that the responsible effector lymphocytes were contained in Leu-11+ and M1+ subsets, but not in the T3+ or T4+ subsets. The phenotypes of the effector cells active in the lysis of hepatitis A virus-infected cells are similar to those of human natural killer cells that lyse K562 cells. Human PBL produced high titers of interferon-alpha (IFN-alpha) when exposed to hepatitis A virus-infected cells. These results imply that hepatitis A virus infection may be controlled by lymphocyte responses in the liver, i.e., by lymphocyte-mediated lysis of the hepatitis A virus-infected cells, and by the production of high titers of IFN-alpha by lymphocytes exposed to hepatitis A virus-infected cells. Furthermore, these results, along with the observations that hepatitis A virus infection results in a persistent noncytocidal infection in vitro, support the hypothesis that lysis of hepatocytes infected with hepatitis A virus is by lymphocyte-mediated cytotoxicity and not by virus-induced destruction of the liver cell.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3926897

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Hepatology.

Authors:  P M Harrison; J Y Lau; R Williams
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

Review 2.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 3.  Innate and adaptive immune responses against picornaviruses and their counteractions: An overview.

Authors:  Andreas Dotzauer; Leena Kraemer
Journal:  World J Virol       Date:  2012-06-12

Review 4.  Role of natural killer cells in experimental murine myocarditis.

Authors:  C J Gauntt; E K Godeny; C W Lutton; G Fernandes
Journal:  Springer Semin Immunopathol       Date:  1989

5.  Characterization with monoclonal antibodies of human lymphocytes active in natural killing and antibody-dependent cell-mediated cytotoxicity of dengue virus-infected cells.

Authors:  I Kurane; D Hebblewaite; F A Ennis
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

Review 6.  Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.

Authors:  Christopher M Walker
Journal:  Cold Spring Harb Perspect Med       Date:  2019-09-03       Impact factor: 6.915

7.  Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus.

Authors:  G Rappocciolo; J F Toso; D J Torpey; P Gupta; C R Rinaldo
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

8.  Virological course of hepatitis A virus as determined by real time RT-PCR: Correlation with biochemical, immunological and genotypic profiles.

Authors:  Zahid Hussain; Bhudev C Das; Syed A Husain; Sunil K Polipalli; Tanzeel Ahmed; Nargis Begum; Subhash Medhi; Alice Verghese; Mohammad Raish; Apiradee Theamboonlers; Yong Poovorawan; Premashis Kar
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

9.  Immunological aspects of the prevention of viral diseases. WHO Workshop.

Authors: 
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

10.  Mimicry of the immunodominant conformation-dependent antigenic site of hepatitis A virus by motifs selected from synthetic peptide libraries.

Authors:  S Mattioli; L Imberti; R Stellini; D Primi
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.